Article info
Review
Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
- Correspondence to Dr A J Mitchell, Department of Liaison Psychiatry, Brandon Unit, Leicester General Hospital, Leicester LE5 4PWl, UK; alex.mitchell{at}leicspart.nhs.uk
Citation
Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?
Publication history
- First published July 20, 2010.
Online issue publication
July 20, 2010
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies
- Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis
- Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease
- New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist
- CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
- Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study
- Use of laboratory and imaging investigations in dementia
- Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study
- Mild cognitive impairment in primary care: a clinical review
- Clinical trials in mild cognitive impairment: lessons for the future